Nkarta Therapeutics

Nkarta’s natural killers flash potential as next-gen cell therapies for cancer

Two natural killer (NK) cell therapy candidates from Nkarta now have preliminary Phase 1 clinical data suggesting these therapies are helping patients in two types of blood cancers. Nkarta therapies based on engineered NK cells could offer both efficacy and safety advantages over the first generations of cell therapies, which are made from a patient’s own T cells.

By Frank Vinluan

BioPharma, Policy

Let data – not politics – guide development of Covid-19 drugs, vaccines, biotech execs urge

In an open letter published by BIO, the executives emphasized the importance of science-driven evaluation of medicines and regulatory independence. The letter came amid growing concern about political pressure over the FDA, as well as lack of diversity in trials and companies being too quick to announce data that are inconclusive.

By Alaric DeArment